Abu Dhabi launches daily oral obesity treatment in major healthcare push
It offers a more flexible and convenient alternative to traditional therapies, supporting sustained care continuity for patients
25 April, 2026
TT
16
The Department of Health – Abu Dhabi (DoH) has launched a daily oral treatment option for obesity under its Personalised Weight Management Programme, in collaboration with the Abu Dhabi Public Health Centre (ADPHC).
The programme combines medical treatment, behavioural support and continuous digital monitoring, aiming to improve long-term health outcomes and quality of life, a WAM report said.
Focus on adherence and patient-centred care
The new oral option is designed to address one of the key challenges in obesity management: long-term treatment adherence. It offers a more flexible and convenient alternative to traditional therapies, supporting sustained care continuity for patients.
Noura Khamis Al Ghaithi, under-secretary of DoH, said the initiative reflects Abu Dhabi’s commitment to integrated, patient-centred healthcare.
Read more-New weight-loss pill lands in UAE: Here’s what you need to know
“The initiative reflects Abu Dhabi’s approach to advancing integrated, patient-centred care that responds to real-life challenges, particularly adherence,” she said.
She added that expanding access to innovative therapies supports better outcomes and long-term quality of life.
Global milestone in obesity treatment access
The UAE is now the second country globally, after the US, to approve this treatment for adults living with obesity or those overweight with related conditions, reinforcing Abu Dhabi’s position in healthcare innovation.
As part of the rollout, Imperial College London Diabetes and Endocrine Centre (ICLDC) will deliver the treatment to eligible patients through a structured programme that combines digital monitoring, personalised clinical care and integrated coverage.
New GLP-1 therapy and coverage model
The treatment, Foundayo (orforglipron), is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate appetite and food intake, supporting weight management outcomes.
Rashid Alsuwaidi, director-general of ADPHC, said the initiative also focuses on behavioural change and sustainable lifestyle support.
“The programme focuses on addressing behavioural challenges and enabling individuals to adopt sustainable healthy habits through practical and flexible solutions,” he said.
The treatment will be covered for eligible adults under the programme, expanding access to comprehensive obesity care in the emirate.

























